Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder

Halbreich, Uriel; Petty, F.; Yonkers, Kimberly A.; Gl, Kramer; Aj, Rush; Kw, Bibi

doi:10.1176/ajp.153.5.718

Cited by 77 publications

(13 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A reduced sensitivity in the luteal phase to GABAergic substances among PMS patients is consistent with our previous results, where PMS patients showed a reduced responsiveness to diazepam in the luteal phase compared to control subjects [4]. PMS patients with a prior history of depression have been reported to have constantly low plasma levels of GABA throughout the menstrual cycle, whereas PMS patients with no psychiatric history showed decreasing plasma levels of GABA in the late luteal phase compared to the follicular phase [36]. These findings are suggestive of a decreased GABA function in PMS patients.…”

Section: Discussionsupporting

confidence: 90%

“…This finding is also consistent with results from our diazepam-challenge study where a significant increase in benzodiazepine sensitivity was noted between cycle phases in control subjects [4]. Control subjects have been reported to have increasing plasma levels of GABA in the late luteal phase compared to the midfollicular phase [36]. Postmenopausal women have also been shown to increase their sensitivity to benzodiazepines during progesterone treatment as measured by several psychomotor tests [49].…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Patients with Premenstrual Syndrome Have a Different Sensitivity to a Neuroactive Steroid during the Menstrual Cycle Compared to Control Subjects

et al. 1998

View full text Add to dashboard Cite

We have evaluated the functional sensitivity to a neuroactive steroid in 12 women with and 12 women without premenstrual syndrome (PMS) at two stages of the menstrual cycle, by comparing the effects of three increasing doses of intravenous pregnanolone (3α-hydroxy-5β-pregnan-20-one) on saccadic eye velocity (SEV) and self-rated sedation. Control subjects in the follicular and luteal phase showed a significant reduction in SEV after pregnanolone injections compared to vehicle. In PMS patients, pregnanolone injections induced a significant dose-related decrease in SEV compared to vehicle only in the follicular phase, not in the luteal phase. After pregnanolone injections, sedation scores increased significantly from vehicle among control subjects in the luteal phase but not among PMS patients in either cycle phase. High-severity PMS patients responded with less decrease in SEV and less increase in sedation scores following pregnanolone injections compared to low-severity patients. Control subjects increased their SEV response to pregnanolone in the luteal phase compared to the follicular phase, whereas PMS patients did not. These findings are compatible with a decreased GABA_A-receptor sensitivity in brain areas controlling saccadic eye movements among PMS patients in the late luteal phase.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 87%

Patients with Premenstrual Syndrome Have a Different Sensitivity to a Neuroactive Steroid during the Menstrual Cycle Compared to Control Subjects

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Sex differences in GABA in MDD cases have also been reported previously (Sanacora et al, 1999), although few have focused on this issue and designed studies to avoid confounding the associations among sex, hormones, medications, and GABA. In fact, earlier studies reported that GABA levels decreased in the mid-follicular menstrual cycle stage among healthy women (Halbreich et al, 1996), although this was not replicated at the level of cortical GABA levels and gonadal hormones (Epperson et al, 2006). …”

Section: Towards Determination Of Mechanismsmentioning

confidence: 89%

Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease

Goldstein

Handa

Tobet

2014

Frontiers in Neuroendocrinology

View full text Add to dashboard Cite

Comorbidity of major depressive disorder (MDD) and cardiovascular disease (CVD) represents the fourth leading cause of morbidity and mortality worldwide, and women have a two times greater risk than men. Thus understanding the pathophysiology has widespread implications for attenuation and prevention of disease burden. We suggest that sex-dependent MDD-CVD comorbidity may result from alterations in fetal programming consequent to the prenatal maternal environments that produce excess glucocorticoids, which then drive sex-dependent developmental alterations of the fetal hypothalamic-pituitary-adrenal (HPA) axis circuitry impacting mood, stress regulation, autonomic nervous system (ANS), and the vasculature in adulthood. Evidence is consistent with the hypothesis that disruptions of pathways associated with gamma aminobutyric acid (GABA) in neuronal and vascular development and growth factors have critical roles in key developmental periods and adult responses to injury in heart and brain. Understanding the potential fetal origins of these sex differences will contribute to development of novel sex-dependent therapeutics.

show abstract

“…An altered sex hormone profile in PMDD has been reported, with lower progesterone levels found in patients compared to controls [93, 94] as well as decreased levels of the anxiolytic progesterone metabolite allopregnanolone during the LP in patients [94, 95]. Progesterone produces its anxiolytic/hypnotic effects via allopregnanolone's binding to GABA A -receptors [96, 97], and some have found lower plasma GABA concentrations [98] and a decreased GABA A -receptor sensitivity [99] during the LP in PMDD patients compared to controls. Results of prior drug trials have found the most effective treatment of PMDD to date to be selective serotonin reuptake inhibitors (SSRIs) and they have become the most common clinical treatment for the disorder [100].…”

Section: Premenstrual Dysphoric Disordermentioning

confidence: 99%

Sleep, Hormones, and Circadian Rhythms throughout the Menstrual Cycle in Healthy Women and Women with Premenstrual Dysphoric Disorder

Shechter

Boivin

2010

International Journal of Endocrinology

124

View full text Add to dashboard Cite

A relationship exists between the sleep-wake cycle and hormone secretion, which, in women, is further modulated by the menstrual cycle. This interaction can influence sleep across the menstrual cycle in healthy women and in women with premenstrual dysphoric disorder (PMDD), who experience specific alterations of circadian rhythms during their symptomatic luteal phase along with sleep disturbances during this time. This review will address the variation of sleep at different menstrual phases in healthy and PMDD women, as well as changes in circadian rhythms, with an emphasis on their relationship with female sex hormones. It will conclude with a brief discussion on nonpharmacological treatments of PMDD which use chronotherapeutic methods to realign circadian rhythms as a means of improving sleep and mood in these women.

show abstract

Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder

Cited by 77 publications

References 3 publications

Patients with Premenstrual Syndrome Have a Different Sensitivity to a Neuroactive Steroid during the Menstrual Cycle Compared to Control Subjects

Patients with Premenstrual Syndrome Have a Different Sensitivity to a Neuroactive Steroid during the Menstrual Cycle Compared to Control Subjects

Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease

Sleep, Hormones, and Circadian Rhythms throughout the Menstrual Cycle in Healthy Women and Women with Premenstrual Dysphoric Disorder

Contact Info

Product

Resources

About